Johnson & Johnson (JNJ) Stock: Plunges 5% Despite Strong Q3 Earnings

TLDR Johnson & Johnson (JNJ) stock drops 5.39% despite beating Q3 earnings forecasts. JNJ reports $25.4 billion in Q3 revenue, topping Wall Street’s $25.28B estimate. MedTech revenue misses expectations as international market pressures weigh on JNJ. TREMFYA sales surge 68% to $2.4 billion, supporting strong pharmaceutical growth. Johnson & Johnson targets a mid-2027 spin-off of [...]

The post Johnson & Johnson (JNJ) Stock: Plunges 5% Despite Strong Q3 Earnings appeared first on Blockonomi.